Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced ...
Gain insights into Paysign, Inc.'s Q4 2024 performance, driven by 212% growth in patient affordability revenue.
13h
We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...
Paysign (PAYS) delivered above-consensus guidance for both Q1 2025 and for the full year, as the company expects its patient ...
Reports Q4 revenue $1.4M vs. $0 last year. “As expected, 2024 was a transformative year for the company and our momentum has continued into ...
Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular ...
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback